Publications

2025

• Safari M, Scotto L, Basseville A, Litman T, Xue H, Petrukhin L, Zhou P, Remotti HE, Ku A, Morales DV, Damoci C, Zhu M, Maddipati R, Hull K, Roby RW,Olive KP, Fojo T, Romo D, Bates SE. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma. Drug Resistance Updates, 2025 October. 10.1016/j.drup.2025.101312
• Cordier C, Jézéquel P, Campone M, Panloup F, Basseville A. HABiC: an algorithm based on the exact computation of the Kantorovich-Rubinstein optimizer for binary classification in transcriptomics. Bioinformatics, Juin 2025. DOI: 10.1093/bioinformatics/btaf310

2024

• Jézéquel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel JS, Juin PP, Ben Azzouz F, Campone M. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype. Breast Cancer, 2024 May. DOI: 10.1007/s12282-024-01597-z. Link for the accepted manuscript version:

  PDF

2022

• Bonneaud TL, Lefebvre CC, Nocquet L, Basseville A, Roul J, Weber H, Campone M, Juin PP, Souazé F. Targeting of MCL-1 in breast cancer associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death & Disease, 2022 Sept. DOI: 10.1038/s41419-022-05214-9
• Basseville A, Cordier C, Ben Azzouz F, Gouraud W, Lasla H, Panloup F, Campone M, Jézéquel P. Brain neural progenitors are new predictive biomarkers for breast cancer hormonotherapy. Cancer Research Communications. 2022 Jul. DOI: 10.1158/2767-9764.CRC-21-0090
• Basseville A, Violet PC, Safari M, Sourbier C, Linehan WM, Robey RW, Levine M, Sackett DL, Bates SE. A Histone deacetylase inhibitor induces acetyl-CoA depletion leading to lethal metabolic stress in RAS-pathway activated cells. Cancers. 2022 May, 14(11), 2643. DOI: 10.3390/cancers14112643
• Robey RW, Lusvarghi S, Chau CH, Basseville A, Figg WD, Ambudkar SV, Bates SE. Drug transporters: molecular characterization and role in drug disposition, 3rd edition, Chapter 12. Guofeng You & Marilyn Morris (Eds). New York, John Wiley and Sons, 2022 April. DOI: 10.1002/9781119739883.ch12
• Belaid NM, Basseville A, Andre-Grégoire G, Fetiveau A, Maillet L, Guillonneau F, Leduc M, Guette C, Desaubry L, Gavard J, Gautier F, Juin PP. BCL-xL antagonizes the deleterious effects of KRAS on mitochondrial scaffolding. Biorxiv preprint, 2022 April. DOI: 10.1101/2022.04.13.488211

2021

• Jézéquel P, Gouraud W, Ben Azzouz F, Basseville A, Juin PP, Lasla H, Campone M. Intérêt de l’outil web bc-GenExMiner en oncologie. Bull Cancer 2021 Nov. DOI: 10.1016/j.bulcan.2021.05.008
• Safari M, Litman T, Robey RW, Aguilera A, Chakraborty A, Reinhold W, Basseville A, Petrukhin L, Scotto L, O'Connor O, Pommier Y, Fojo A, Bates SE. R-loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin. Mol Cancer Research, 2021 June. DOI: 10.1158/1541-7786.MCR-20-0833

2017

• Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP. BCL-X(L) directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017 Oct. DOI: 10.1038/s41467-017-01079-1

2016

• Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H,Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016 Oct. DOI: 10.18632/oncotarget.12001
• Basseville A, Hall MD, Chau CH, Robey RW, Gottesman MM, Figg WD, Bates SE. ABC Transporters, 40 Years on, Chapter 9. Anthony M. George (Ed.). Springer International Publishing, 2016 Dec. DOI: 10.1007/978-3-319-23476-2_9

2015

• Basseville A, Bates S, Fojo T. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. Nat Rev Clin Oncol, 2015 Aug. DOI: 10.1038/nrclinonc.2015.125
• Serrano OK, Parrow NL, Violet PC, Yang J, Zornjak J, Basseville A, Levine M. Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model. Free Radic Biol Med, 2015 Oct. DOI: 10.1016/j.freeradbiomed.2015.06.032

2014

• Basseville A, Robey RW, Bahr JC, Bates SE. Drug transporters: molecular characterization and role in drug disposition, Chapter 11. Guofeng You & Marilyn Morris (Eds). New York, John Wiley and Sons, 2014 Aug. DOI: 10.1002/9781118705308.ch11

2013

• Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S. Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biol Ther, 2013 Feb. DOI: 10.4161/cbt.22957
• Basseville A, Figg WD, Sparreboom A, Bates SE. Pharmacogenomics of Human Drug Transporters: Clinical Impacts, Chapter 14. Toshihisa Ishikawa, Richard B. Kim & Jörg König (Eds). New York, John Wiley and Sons, 2013 Mar. DOI: 10.1002/9781118353240.ch14

2012

• Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey R, Hegde RS, Bates SE. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Cancer Research, 2012 Jul. DOI: 10.1158/0008-5472.CAN-11-2008
• Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat, 2012 Mar. DOI: 10.1016/j.drup.2012.02.002

2011

• Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm, 2011 Dec. DOI: 10.1021/mp200329f
• Basseville A & Bates SE. Gout, genetics and ABC transporters. F1000 Biol Rep, 2011. Nov. DOI: 10.3410/B3-23
• Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer, 2011 Jul. DOI: 10.1186/1476-4598-10-80